-
公开(公告)号：EP4380968A1
公开(公告)日：2024-06-12
申请号：EP22761216.5
申请日：2022-08-05
CPC分类号： C07K14/70539 , A61K38/1774 , A61P35/00 , C07K2319/3020130101 , C07K2317/7320130101 , C07K16/2818 , A61K39/39558
-
公开(公告)号：EP4380595A1
公开(公告)日：2024-06-12
申请号：EP22761217.3
申请日：2022-08-05
CPC分类号： C07K14/70539 , A61K38/1774 , A61P35/00 , C07K2319/3020130101 , C07K2317/7320130101 , C07K16/2818 , A61K39/39558
-
公开(公告)号：EP4380605A1
公开(公告)日：2024-06-12
申请号：EP22764658.5
申请日：2022-08-05
IPC分类号： A61K39/00 , A61K39/395 , A61P35/00 , C07K14/74 , C07K14/705 , C07K16/28
CPC分类号： C07K14/70539 , C07K14/70596 , A61P35/00 , C07K2319/3020130101 , C07K16/2803 , A61K39/39558 , A61K2039/50520130101 , A61K39/39
-
公开(公告)号：EP4130029A1
公开(公告)日：2023-02-08
申请号：EP21190005.5
申请日：2021-08-05
摘要： The invention relates to pharmaceutical compositions comprising HLA fusion proteins for use in treating neoplastic disease. The invention also provides combination medicaments comprising both HLA fusion proteins and checkpoint inhibitors, for use in treating cancer.
-
公开(公告)号：EP4129323A1
公开(公告)日：2023-02-08
申请号：EP21190004.8
申请日：2021-08-05
摘要： The invention provides a method of obtaining an HLA-B57 fusion protein, said fusion protein comprising a variant HLA-B57 polypeptide bearing at least, one, or two amino acid substitutions conferring increased stability and expression. The invention also provides an isolated HLA-B57 fusion protein, or a nucleic acid, or a vector encoding said HLA-B57 fusion protein, for use in treating medical conditions such as cancer.
-
-
-
-
搜索结果
5 条记录 (耗时 0.01 秒)
